Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 2,274 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ovary Disease Clear all

Conditions: Ovarian Neoplasms, Fallopian Tube Neoplasms, Primary Peritoneal Neoplasms
Interventions: Pegylated L-Asparaginase; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ovarian Cancer
Interventions: Liposomal Doxorubicin, Topotecan; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Ovarian Cancer
Interventions: Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 50 Years to 74 Years · Female only
Enrollment: 8,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2028
U.S. locations: 12
States / cities: Miami, Florida • Des Moines, Iowa • Minneapolis, Minnesota + 8 more

Conditions: Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions: STRO-002; Drug
Lead sponsor: Sutro Biopharma, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 23
States / cities: Tucson, Arizona • Los Angeles, California • San Francisco, California + 19 more

Conditions: Ovarian Cancer
Interventions: Perifosine, Docetaxel; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cervical Carcinoma, Fallopian Tube Carcinoma, Malignant Solid Neoplasm, Malignant Uterine Neoplasm, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Vulvar Carcinoma
Interventions: Best Practice, Cilostazol, Cryocompression Therapy, Paclitaxel, Quality-of-Life Assessment; Other · Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma
Interventions: AL58805, AL3818, Temozolomide (TMZ), CCNU; Drug
Lead sponsor: Advenchen Pharmaceuticals, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Polycystic Ovary Syndrome
Interventions: Oral Cinnamon Extract, Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 23 Years to 47 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer
Interventions: immunological diagnostic method, physiologic testing; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Up to 120 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Ovarian Cancer
Interventions: intraperitoneal chemotherapy, educational intervention, medical chart review, questionnaire administration, assessment of therapy complications, end-of-life treatment/management, psychosocial assessment and care, quality-of-life assessment; Drug · Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Duarte, California

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma
Interventions: arsenic trioxide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 40 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Ovarian Cancer
Interventions: Pre-study Questionnaire, Educational Presentations, CAM Therapies, Post-study Questionnaire; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions: filgrastim, carboplatin, cyclophosphamide, etoposide, autologous bone marrow transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: Up to 35 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma, Gastrointestinal Cancer, Lung Cancer, Prostate Cancer, Breast Cancer
Interventions: QXL138AM Injection every 2 weeks by IV Infusion; Biological
Lead sponsor: Nammi Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 11
States / cities: Los Angeles, California • Newport, California • Denver, Colorado + 5 more

Conditions: Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Cervical Cancer, Uterine Cancer
Interventions: Audio + Radio (AURA); Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • San Antonio, Texas

Conditions: Subfertility, Anovulatory, Obese
Interventions: Intensive Dietary Intervention, Placebo; Behavioral
Lead sponsor: Amy E Rothberg; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Adenocarcinoma, Colorectal Cancer, Ovarian Cancer, Breast Cancer
Interventions: PANVAC-V, PANVAC-F, Sargramostim (GM-CSF, Leukine); Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: gemcitabine hydrochloride, topotecan hydrochloride; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms
Interventions: LY3537982, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin, Carboplatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine, tetanus toxoid helper peptide, carboplatin, paclitaxel, conventional surgery; Biological · Drug · Procedure
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Soft-tissue Sarcoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Ovarian Cancer, KRAS Mutation-Related Tumors
Interventions: Spedox-6, Pegfilgrastim, Filgrastim; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Orange, California

Conditions: Cervical Cancer, Ovarian Cancer
Interventions: etoposide; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1993
U.S. locations: 47
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 38 more

Conditions: Menopause, Premature
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Ovarian Cancer
Interventions: Mobile Application; Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan

Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer

Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers

A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers

The Effect of Cinnamon Extract on Insulin Resistance Parameters in Polycystic Ovary Syndrome: A Pilot Study

Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants

Palliative Care During Intraperitoneal Chemotherapy in Patients With Ovarian Cancer

Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors

Pilot Program to Personalize Care & Improve Quality of Life for Women With Ovarian Cancer

Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

Connecting Audio and Radio Sensing Systems to Improve Care at Home

The Effects of an Intensive Lifestyle Intervention on Reproductive Outcomes

PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer

Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer

Impact of Treatment Induced Premature Menopause on Quality of Life

Value-based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)